logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Incannex Healthcare Limited

IXHL

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine aā€¦ read more

Healthcare

Drug Manufacturersā€”Specialty & Generic

1 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.38

Price

-3.77%

-$0.02

$0.40

Previous Close

$0.38

Open

Premium

52w Discount
Market Cap

$11.188m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$98k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$21.743m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.20

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$965k

$11.106m

Assets

$10.141m

Liabilities

$4.097m

Debt
Debt to Assets

36.9%

-0.2x

Debt to EBITDA
Free Cash Flow

-$12.801m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.